Successful  ||| S:0 E:11 ||| JJ
treatment  ||| S:11 E:21 ||| NN
of  ||| S:21 E:24 ||| IN
bisphosphonate-related  ||| S:24 E:47 ||| JJ
osteonecrosis  ||| S:47 E:61 ||| NN
of  ||| S:61 E:64 ||| IN
the  ||| S:64 E:68 ||| DT
jaw  ||| S:68 E:72 ||| NN
( ||| S:72 E:73 ||| -LRB-
BRONJ ||| S:73 E:78 ||| NNP
)  ||| S:78 E:80 ||| -RRB-
patients  ||| S:80 E:89 ||| NNS
with  ||| S:89 E:94 ||| IN
sitafloxacin ||| S:94 E:106 ||| NNS
:  ||| S:106 E:108 ||| :
new  ||| S:108 E:112 ||| JJ
strategies  ||| S:112 E:123 ||| NNS
for  ||| S:123 E:127 ||| IN
the  ||| S:127 E:131 ||| DT
treatment  ||| S:131 E:141 ||| NN
of  ||| S:141 E:144 ||| IN
BRONJ  ||| S:144 E:150 ||| NNP
BRONJ  ||| S:150 E:156 ||| NNP
has  ||| S:156 E:160 ||| VBZ
become  ||| S:160 E:167 ||| VBN
a  ||| S:167 E:169 ||| DT
well-known ||| S:169 E:179 ||| JJ
,  ||| S:179 E:181 ||| ,
occasionally  ||| S:181 E:194 ||| RB
severe  ||| S:194 E:201 ||| JJ
side  ||| S:201 E:206 ||| NN
effect  ||| S:206 E:213 ||| NN
of  ||| S:213 E:216 ||| IN
bisphosphonate  ||| S:216 E:231 ||| JJ
therapy ||| S:231 E:238 ||| NN
,  ||| S:238 E:240 ||| ,
as  ||| S:240 E:243 ||| RB
well  ||| S:243 E:248 ||| RB
as  ||| S:248 E:251 ||| IN
a  ||| S:251 E:253 ||| DT
clinical  ||| S:253 E:262 ||| JJ
problem ||| S:262 E:269 ||| NN
.  ||| S:269 E:271 ||| .
Although  ||| S:271 E:280 ||| IN
treatment  ||| S:280 E:290 ||| NN
recommendations  ||| S:290 E:306 ||| NNS
exist ||| S:306 E:311 ||| VBP
,  ||| S:311 E:313 ||| ,
no  ||| S:313 E:316 ||| DT
standard  ||| S:316 E:325 ||| JJ
therapy  ||| S:325 E:333 ||| NN
has  ||| S:333 E:337 ||| VBZ
yet  ||| S:337 E:341 ||| RB
been  ||| S:341 E:346 ||| VBN
established  ||| S:346 E:358 ||| VBN
for  ||| S:358 E:362 ||| IN
BRONJ ||| S:362 E:367 ||| NNP
.  ||| S:367 E:369 ||| .
Also ||| S:369 E:373 ||| RB
,  ||| S:373 E:375 ||| ,
these  ||| S:375 E:381 ||| DT
recommendations  ||| S:381 E:397 ||| NNS
identify  ||| S:397 E:406 ||| VBP
several  ||| S:406 E:414 ||| JJ
limitations  ||| S:414 E:426 ||| NNS
that  ||| S:426 E:431 ||| WDT
prevent  ||| S:431 E:439 ||| VBP
clinicians  ||| S:439 E:450 ||| VBN
from  ||| S:450 E:455 ||| IN
confidently  ||| S:455 E:467 ||| FW
diagnosing  ||| S:467 E:478 ||| FW
BRONJ ||| S:478 E:483 ||| FW
.  ||| S:483 E:485 ||| .
The  ||| S:485 E:489 ||| DT
aim  ||| S:489 E:493 ||| NN
of  ||| S:493 E:496 ||| IN
the  ||| S:496 E:500 ||| DT
present  ||| S:500 E:508 ||| JJ
study  ||| S:508 E:514 ||| NN
was  ||| S:514 E:518 ||| VBD
to  ||| S:518 E:521 ||| TO
establish  ||| S:521 E:531 ||| VB
a  ||| S:531 E:533 ||| DT
treatment  ||| S:533 E:543 ||| NN
approach  ||| S:543 E:552 ||| NN
in  ||| S:552 E:555 ||| IN
which  ||| S:555 E:561 ||| WDT
all  ||| S:561 E:565 ||| DT
patients  ||| S:565 E:574 ||| NNS
with  ||| S:574 E:579 ||| IN
exposed ||| S:579 E:586 ||| VBN
,  ||| S:586 E:588 ||| ,
infected  ||| S:588 E:597 ||| JJ
bone  ||| S:597 E:602 ||| NN
or  ||| S:602 E:605 ||| CC
intraoral ||| S:605 E:614 ||| CD
/ ||| S:614 E:615 ||| CD
extraoral  ||| S:615 E:625 ||| CD
fistulas  ||| S:625 E:634 ||| NNS
were  ||| S:634 E:639 ||| VBD
treated  ||| S:639 E:647 ||| VBN
with  ||| S:647 E:652 ||| IN
sitafloxacin  ||| S:652 E:665 ||| NNS
( ||| S:665 E:666 ||| -LRB-
STFX ||| S:666 E:670 ||| NNP
) ||| S:670 E:671 ||| -RRB-
.  ||| S:671 E:673 ||| .
We  ||| S:673 E:676 ||| PRP
examined  ||| S:676 E:685 ||| VBD
20  ||| S:685 E:688 ||| CD
BRONJ  ||| S:688 E:694 ||| NN
patients ||| S:694 E:702 ||| NNS
,  ||| S:702 E:704 ||| ,
fourteen  ||| S:704 E:713 ||| VBG
with  ||| S:713 E:718 ||| IN
cancer  ||| S:718 E:725 ||| NN
and  ||| S:725 E:729 ||| CC
six  ||| S:729 E:733 ||| CD
with  ||| S:733 E:738 ||| IN
osteoporosis ||| S:738 E:750 ||| NN
.  ||| S:750 E:752 ||| .
We  ||| S:752 E:755 ||| PRP
used  ||| S:755 E:760 ||| VBD
the  ||| S:760 E:764 ||| DT
current  ||| S:764 E:772 ||| JJ
updated  ||| S:772 E:780 ||| JJ
definition  ||| S:780 E:791 ||| NN
of  ||| S:791 E:794 ||| IN
BRONJ  ||| S:794 E:800 ||| NNP
( ||| S:800 E:801 ||| -LRB-
12 ||| S:801 E:803 ||| CD
) ||| S:803 E:804 ||| -RRB-
,  ||| S:804 E:806 ||| ,
except  ||| S:806 E:813 ||| IN
that  ||| S:813 E:818 ||| WDT
we  ||| S:818 E:821 ||| PRP
included  ||| S:821 E:830 ||| VBD
patients  ||| S:830 E:839 ||| NNS
who  ||| S:839 E:843 ||| WP
had  ||| S:843 E:847 ||| VBD
shown  ||| S:847 E:853 ||| VBN
symptoms  ||| S:853 E:862 ||| NNS
for  ||| S:862 E:866 ||| IN
a  ||| S:866 E:868 ||| DT
minimum  ||| S:868 E:876 ||| NN
of  ||| S:876 E:879 ||| IN
only  ||| S:879 E:884 ||| RB
one  ||| S:884 E:888 ||| CD
month ||| S:888 E:893 ||| NN
,  ||| S:893 E:895 ||| ,
rather  ||| S:895 E:902 ||| RB
than  ||| S:902 E:907 ||| IN
two  ||| S:907 E:911 ||| CD
months ||| S:911 E:917 ||| NNS
.  ||| S:917 E:919 ||| .
Thus  ||| S:919 E:924 ||| RB
half  ||| S:924 E:929 ||| NN
of  ||| S:929 E:932 ||| IN
our  ||| S:932 E:936 ||| PRP$
patients  ||| S:936 E:945 ||| NNS
had  ||| S:945 E:949 ||| VBD
infection  ||| S:949 E:959 ||| NN
with  ||| S:959 E:964 ||| IN
no  ||| S:964 E:967 ||| DT
exposed ||| S:967 E:974 ||| NN
,  ||| S:974 E:976 ||| ,
necrotic  ||| S:976 E:985 ||| JJ
bone  ||| S:985 E:990 ||| NN
in  ||| S:990 E:993 ||| IN
the  ||| S:993 E:997 ||| DT
oral  ||| S:997 E:1002 ||| JJ
cavity ||| S:1002 E:1008 ||| NN
.  ||| S:1008 E:1010 ||| .
We  ||| S:1010 E:1013 ||| PRP
purposely  ||| S:1013 E:1023 ||| RB
excluded  ||| S:1023 E:1032 ||| VBN
all  ||| S:1032 E:1036 ||| DT
patients  ||| S:1036 E:1045 ||| NNS
exhibiting  ||| S:1045 E:1056 ||| VBG
no  ||| S:1056 E:1059 ||| DT
signs  ||| S:1059 E:1065 ||| NNS
of  ||| S:1065 E:1068 ||| IN
infection  ||| S:1068 E:1078 ||| NN
( ||| S:1078 E:1079 ||| -LRB-
current  ||| S:1079 E:1087 ||| JJ
Stages  ||| S:1087 E:1094 ||| NNP
0  ||| S:1094 E:1096 ||| CD
and  ||| S:1096 E:1100 ||| CC
1 ||| S:1100 E:1101 ||| CD
) ||| S:1101 E:1102 ||| -RRB-
.  ||| S:1102 E:1104 ||| .
In  ||| S:1104 E:1107 ||| IN
addition ||| S:1107 E:1115 ||| NN
,  ||| S:1115 E:1117 ||| ,
each  ||| S:1117 E:1122 ||| DT
potentially  ||| S:1122 E:1134 ||| RB
causative  ||| S:1134 E:1144 ||| JJ
organism  ||| S:1144 E:1153 ||| NN
was  ||| S:1153 E:1157 ||| VBD
isolated  ||| S:1157 E:1166 ||| VBN
from  ||| S:1166 E:1171 ||| IN
pus  ||| S:1171 E:1175 ||| VBG
collected  ||| S:1175 E:1185 ||| VBN
from  ||| S:1185 E:1190 ||| IN
an  ||| S:1190 E:1193 ||| DT
intraoral  ||| S:1193 E:1203 ||| NN
or  ||| S:1203 E:1206 ||| CC
extraoral  ||| S:1206 E:1216 ||| JJ
fistula  ||| S:1216 E:1224 ||| NN
in  ||| S:1224 E:1227 ||| IN
ten  ||| S:1227 E:1231 ||| JJ
patients  ||| S:1231 E:1240 ||| NNS
on  ||| S:1240 E:1243 ||| IN
their  ||| S:1243 E:1249 ||| PRP$
first  ||| S:1249 E:1255 ||| JJ
visit  ||| S:1255 E:1261 ||| NN
to  ||| S:1261 E:1264 ||| TO
our  ||| S:1264 E:1268 ||| PRP$
department.  ||| S:1268 E:1280 ||| CD
90 ||| S:1280 E:1282 ||| CD
%  ||| S:1282 E:1284 ||| NN
of  ||| S:1284 E:1287 ||| IN
the  ||| S:1287 E:1291 ||| DT
patients  ||| S:1291 E:1300 ||| NNS
had  ||| S:1300 E:1304 ||| VBD
received  ||| S:1304 E:1313 ||| VBN
a  ||| S:1313 E:1315 ||| DT
course  ||| S:1315 E:1322 ||| NN
of  ||| S:1322 E:1325 ||| IN
treatment  ||| S:1325 E:1335 ||| NN
with  ||| S:1335 E:1340 ||| IN
common  ||| S:1340 E:1347 ||| JJ
antibiotics ||| S:1347 E:1358 ||| NN
.  ||| S:1358 E:1360 ||| .
STFX  ||| S:1360 E:1365 ||| NNP
was  ||| S:1365 E:1369 ||| VBD
administered  ||| S:1369 E:1382 ||| VBN
to  ||| S:1382 E:1385 ||| TO
all  ||| S:1385 E:1389 ||| DT
patients ||| S:1389 E:1397 ||| NNS
.  ||| S:1397 E:1399 ||| .
We  ||| S:1399 E:1402 ||| PRP
then  ||| S:1402 E:1407 ||| RB
re-evaluated  ||| S:1407 E:1420 ||| JJ
the  ||| S:1420 E:1424 ||| DT
lesion  ||| S:1424 E:1431 ||| NN
every  ||| S:1431 E:1437 ||| DT
other  ||| S:1437 E:1443 ||| JJ
week ||| S:1443 E:1447 ||| NN
,  ||| S:1447 E:1449 ||| ,
to  ||| S:1449 E:1452 ||| TO
determine  ||| S:1452 E:1462 ||| VB
whether  ||| S:1462 E:1470 ||| IN
epithelialization  ||| S:1470 E:1488 ||| NN
was  ||| S:1488 E:1492 ||| VBD
present ||| S:1492 E:1499 ||| JJ
.  ||| S:1499 E:1501 ||| .
We  ||| S:1501 E:1504 ||| PRP
recommended  ||| S:1504 E:1516 ||| VBD
surgical  ||| S:1516 E:1525 ||| JJ
treatment  ||| S:1525 E:1535 ||| NN
for  ||| S:1535 E:1539 ||| IN
cases  ||| S:1539 E:1545 ||| NNS
without  ||| S:1545 E:1553 ||| IN
epithelialization  ||| S:1553 E:1571 ||| NN
within  ||| S:1571 E:1578 ||| IN
4  ||| S:1578 E:1580 ||| CD
weeks  ||| S:1580 E:1586 ||| NNS
after  ||| S:1586 E:1592 ||| IN
the  ||| S:1592 E:1596 ||| DT
onset  ||| S:1596 E:1602 ||| NN
of  ||| S:1602 E:1605 ||| IN
administration  ||| S:1605 E:1620 ||| NN
of  ||| S:1620 E:1623 ||| IN
STFX  ||| S:1623 E:1628 ||| NNP
even  ||| S:1628 E:1633 ||| RB
if  ||| S:1633 E:1636 ||| IN
bone  ||| S:1636 E:1641 ||| NN
was  ||| S:1641 E:1645 ||| VBD
not  ||| S:1645 E:1649 ||| RB
exposed  ||| S:1649 E:1657 ||| VBN
at  ||| S:1657 E:1660 ||| IN
the  ||| S:1660 E:1664 ||| DT
lesion.  ||| S:1664 E:1672 ||| CD
19  ||| S:1672 E:1675 ||| CD
of  ||| S:1675 E:1678 ||| IN
our  ||| S:1678 E:1682 ||| PRP$
20  ||| S:1682 E:1685 ||| CD
cases  ||| S:1685 E:1691 ||| NNS
of  ||| S:1691 E:1694 ||| IN
Stages  ||| S:1694 E:1701 ||| NNP
2-3  ||| S:1701 E:1705 ||| NNP
BRONJ  ||| S:1705 E:1711 ||| NNP
responded  ||| S:1711 E:1721 ||| VBD
to  ||| S:1721 E:1724 ||| TO
2-10  ||| S:1724 E:1729 ||| CD
weeks  ||| S:1729 E:1735 ||| NNS
of  ||| S:1735 E:1738 ||| IN
STFX  ||| S:1738 E:1743 ||| NNP
treatment  ||| S:1743 E:1753 ||| NN
by  ||| S:1753 E:1756 ||| IN
entering  ||| S:1756 E:1765 ||| VBG
either  ||| S:1765 E:1772 ||| RB
a  ||| S:1772 E:1774 ||| DT
remission  ||| S:1774 E:1784 ||| NN
or  ||| S:1784 E:1787 ||| CC
healed  ||| S:1787 E:1794 ||| JJ
phase ||| S:1794 E:1799 ||| NN
.  ||| S:1799 E:1801 ||| .
While  ||| S:1801 E:1807 ||| IN
surgery  ||| S:1807 E:1815 ||| NN
was  ||| S:1815 E:1819 ||| VBD
done  ||| S:1819 E:1824 ||| VBN
on  ||| S:1824 E:1827 ||| IN
thirteen  ||| S:1827 E:1836 ||| JJ
cases ||| S:1836 E:1841 ||| NNS
,  ||| S:1841 E:1843 ||| ,
seven  ||| S:1843 E:1849 ||| CD
others  ||| S:1849 E:1856 ||| NNS
reached  ||| S:1856 E:1864 ||| VBD
such  ||| S:1864 E:1869 ||| JJ
phases  ||| S:1869 E:1876 ||| NNS
without  ||| S:1876 E:1884 ||| IN
surgery ||| S:1884 E:1891 ||| NN
.  ||| S:1891 E:1893 ||| .
Every  ||| S:1893 E:1899 ||| DT
patient  ||| S:1899 E:1907 ||| NN
had  ||| S:1907 E:1911 ||| VBD
at  ||| S:1911 E:1914 ||| IN
least  ||| S:1914 E:1920 ||| JJS
one  ||| S:1920 E:1924 ||| CD
bacterial  ||| S:1924 E:1934 ||| JJ
species  ||| S:1934 E:1942 ||| NNS
that  ||| S:1942 E:1947 ||| WDT
showed  ||| S:1947 E:1954 ||| VBD
resistance  ||| S:1954 E:1965 ||| NN
to  ||| S:1965 E:1968 ||| TO
common  ||| S:1968 E:1975 ||| JJ
antibiotics ||| S:1975 E:1986 ||| NN
.  ||| S:1986 E:1988 ||| .
All  ||| S:1988 E:1992 ||| DT
species  ||| S:1992 E:2000 ||| NN
in  ||| S:2000 E:2003 ||| IN
all  ||| S:2003 E:2007 ||| DT
patients  ||| S:2007 E:2016 ||| NNS
were  ||| S:2016 E:2021 ||| VBD
susceptible  ||| S:2021 E:2033 ||| JJ
to  ||| S:2033 E:2036 ||| TO
STFX ||| S:2036 E:2040 ||| NNP
.  ||| S:2040 E:2042 ||| .
Our  ||| S:2042 E:2046 ||| PRP$
results  ||| S:2046 E:2054 ||| NNS
indicate  ||| S:2054 E:2063 ||| VBP
that  ||| S:2063 E:2068 ||| IN
STFX ||| S:2068 E:2072 ||| NNP
,  ||| S:2072 E:2074 ||| ,
with  ||| S:2074 E:2079 ||| IN
or  ||| S:2079 E:2082 ||| CC
without  ||| S:2082 E:2090 ||| IN
minor  ||| S:2090 E:2096 ||| JJ
surgery ||| S:2096 E:2103 ||| NN
,  ||| S:2103 E:2105 ||| ,
gives  ||| S:2105 E:2111 ||| VBZ
a  ||| S:2111 E:2113 ||| DT
high  ||| S:2113 E:2118 ||| JJ
probability  ||| S:2118 E:2130 ||| NN
of  ||| S:2130 E:2133 ||| IN
controlling  ||| S:2133 E:2145 ||| VBG
infection  ||| S:2145 E:2155 ||| NN
in  ||| S:2155 E:2158 ||| IN
BRONJ  ||| S:2158 E:2164 ||| NNP
patients  ||| S:2164 E:2173 ||| NNS
with  ||| S:2173 E:2178 ||| IN
persistent  ||| S:2178 E:2189 ||| JJ
infection  ||| S:2189 E:2199 ||| NN
after  ||| S:2199 E:2205 ||| IN
use  ||| S:2205 E:2209 ||| NN
of  ||| S:2209 E:2212 ||| IN
common  ||| S:2212 E:2219 ||| JJ
antibiotics ||| S:2219 E:2230 ||| NN
,  ||| S:2230 E:2232 ||| ,
leading  ||| S:2232 E:2240 ||| VBG
to  ||| S:2240 E:2243 ||| TO
remission  ||| S:2243 E:2253 ||| VB
and ||| S:2253 E:2256 ||| CC
/ ||| S:2256 E:2257 ||| NNP
or  ||| S:2257 E:2260 ||| CC
complete  ||| S:2260 E:2269 ||| JJ
healing  ||| S:2269 E:2277 ||| NN
in  ||| S:2277 E:2280 ||| IN
95 ||| S:2280 E:2282 ||| CD
%  ||| S:2282 E:2284 ||| NN
of  ||| S:2284 E:2287 ||| IN
patients ||| S:2287 E:2295 ||| NNS
.  ||| S:2295 E:2297 ||| .
